AtaiBeckley (ATAI) Receivables (2022 - 2026)

AtaiBeckley (ATAI) posted quarterly Receivables of $1.5 million for Q1 2026, up 119.49% quarter-over-quarter from $667000.0 in Q4 2025.

Analysis

AtaiBeckley (ATAI) Receivables (2022 - 2026) Analysis & Trends

AtaiBeckley's Receivables history runs 3 years deep, the most recent figure standing at $1.5 million for Q1 2026.

In Q1 2026, Receivables changed N/A year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (changed N/A YoY), while the FY2025 annual figure was $667000.0, up 88.42% from the prior year.
Receivables for Q1 2026 stood at $1.5 million, up from $667000.0 in the prior quarter.
Over five years, Receivables peaked at $313000.0 in Q3 2024 and troughed at $46000.0 in Q3 2025.
A 3-year average of $176000.0 and a median of $172500.0 in 2023 frame the typical range for Receivables.
Peak annual rise in Receivables reached 88.42% in 2025, while the deepest fall reached 88.42% in 2025.
AtaiBeckley's Receivables stood at $354000.0 in 2024, then surged by 88.42% to $667000.0 in 2025, then surged by 119.49% to $1.5 million in 2026.
Business Quant data shows ATAI's Receivables at $1.5 million in Q1 2026, $667000.0 in Q4 2025, and $354000.0 in Q4 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	1.93 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	160.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	1.06 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	912.74 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	215.33 Mn
10	AtaiBeckley	1.61 Bn	1.61 Bn	-	46,000.00

Historic Data

Download Data